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mRNA profiling of the cancer degradome in oesophago–gastric
adenocarcinoma
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S Paterson-Brown4, ACP Riddick2, DR Edwards3, KCH Fearon1, JA Ross1,6 and RJE Skipworth*,1,4,6
1Tissue Injury and Repair Group, Clinical and Surgical Sciences, University of Edinburgh-MRC Centre for Regenerative Medicine, Royal Infirmary
of Edinburgh, 51 Little France Crescent, Edinburgh, UK; 2Edinburgh Urological Cancer Group, Western General Hospital, Edinburgh EH4 2XU, UK;
3School of Biological Sciences, University of East Anglia, Norwich, UK; 4Department of Surgery, Royal Infirmary of Edinburgh, Edinburgh, UK
BACKGROUND: Degradation of the extracellular matrix is fundamental to tumour development, invasion and metastasis. Several
protease families have been implicated in the development of a broad range of tumour types, including oesophago–gastric
(OG) adenocarcinoma. The aim of this study was to analyse the expression levels of all core members of the cancer degradome in
OG adenocarcinoma and to investigate the relationship between expression levels and tumour/patient variables associated with poor
prognosis.
METHODS: Comprehensive expression profiling of the protease families (matrix metalloproteinases (MMPs), members of the ADAM
metalloproteinase-disintegrin family (ADAMs)), their inhibitors (tissue inhibitors of metalloproteinase), and molecules involved in the
c-Met signalling pathway, was performed using quantitative real-time reverse transcription polymerase chain reaction in a cohort of
matched malignant and benign peri-tumoural OG tissue (n¼ 25 patients). Data were analysed with respect to clinico-pathological
variables (tumour stage and grade, age, sex and pre-operative plasma C-reactive protein level).
RESULTS: Gene expression of MMP1, 3, 7, 9, 10, 11, 12, 16 and 24 was upregulated by factors 44-fold in OG adenocarcinoma
samples compared with matched benign tissue (Po0.01). Expression of ADAM8 and ADAM15 correlated significantly with tumour
stage (P¼ 0.048 and P¼ 0.044), and ADAM12 expression correlated with tumour grade (P¼ 0.011).
CONCLUSION: This study represents the first comprehensive quantitative analysis of the expression of proteases and their inhibitors in
human OG adenocarcinoma. These findings implicate elevated ADAM8, 12 and 15 mRNA expression as potential prognostic
molecular markers.
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Oesophageal and junctional adenocarcinomas continue to increase in
incidence and gastric adenocarcinoma remains the fourth commonest
form of cancer worldwide (Pera, 2003). Oesophago–gastric (OG)
adenocarcinoma causes more than a million deaths per annum
(Parkin et al, 2005). Survival is generally poor with 5-year survival
rates in the United Kingdom of 13% and 7.5% for gastric and
oesophageal cancer, respectively (Quinn, 2003). The identification of
biomarkers for diagnosis, treatment and prognosis is therefore an
unmet clinical need that requires urgent attention.
Degradation of the extracellular matrix (ECM) is fundamental to
tumour development and invasion (Egeblad and Werb, 2002; Roy
et al, 2009; Kessenbrock et al, 2010), and evidence suggests that
multiple ECM proteases and their inhibitors are mediators of OG
tumourigenesis (Egeblad and Werb, 2002; Skrzydlewska et al, 2005;
Kessenbrock et al, 2010). Furthermore, it has become evident that
the function of proteases is more complex than believed initially
(Kessenbrock et al, 2010) and, in addition to breaking down
physical barriers, they may also play crucial roles in angiogenesis,
apoptosis, cell migration and shedding of surface adhesion
molecules (Egeblad and Werb, 2002). Examples of such enzyme
systems include the matrix metalloproteinases (MMPs), their
endogenous inhibitors (the tissue inhibitors of metalloproteinases
(TIMPs) (Bourboulia and Stetler-Stevenson, 2010)), and the
ADAM (A Disintegrin And Metalloproteinase) family. Matrix
metalloproteinases are a subfamily of zinc-dependent endopepti-
dases consisting of 24 members divided into five main groups
according to their structure and substrate specificity: collagenases,
gelatinases, membrane type, stromelysins and matrilysins
(Egeblad and Werb, 2002; Bourboulia and Stetler-Stevenson,
2010; Kessenbrock et al, 2010). Most MMPs are secreted into
plasma and are inhibited by a2-macroglobulin secreted by the liver
(Bourboulia and Stetler-Stevenson, 2010). The MMPs are regulated
by the four members of the TIMP family, which each bind
reversibly to MMPs with some specificity; for example, TIMP1
binds preferentially to MMP1, 3, 7 and 9 and is a relatively poor
inhibitor of membrane-type MMPs (Baker et al, 2002; Bourboulia
and Stetler-Stevenson, 2010). The 21 members of the human
ADAM family are transmembrane and secreted metalloproteinases
that are relatives of the MMPs, as both families belong to the
*Correspondence: Dr RJE Skipworth; E-mail: richard.skipworth@ed.ac.uk
5These authors contributed equally to this work.
6These authors are joint senior authors.
Revised 20 March 2012; accepted 25 April 2012; published online 7 June
2012
British Journal of Cancer (2012) 107, 143–149
& 2012 Cancer Research UK All rights reserved 0007 – 0920/12
www.bjcancer.com
M
o
le
c
u
la
r
D
ia
g
n
o
st
ic
s
metzincin superfamily (Edwards et al, 2008; Rocks et al, 2008;
Duffy et al, 2009). In addition to proteolysis, the ADAMs have roles
in cell adhesion mediated by interaction of their disintegrin and
Cys-rich domains with integrins and other receptors (Rocks et al,
2008; Duffy et al, 2009). Approximately 50% of ADAMs contain the
catalytic consensus sequence HEXXH in their protease domain
(Duffy et al, 2009), and it is thought that only these ADAMs
possess protease activity (Duffy et al, 2009). The activity of selected
ADAMs can also be inhibited by certain TIMPs, principally TIMP3
(Amour et al, 1998, 2000; Kashiwagi et al, 2001). There is some
evidence supporting a role for the earliest identified proteases
(MMP2, 7, 9 and TIMP1, 2) in the development of OG cancer
(Rocks et al, 2008; Bourboulia and Stetler-Stevenson, 2010) but
little is known about the role of more recently discovered MMPs,
TIMPs or ADAMs (Rocks et al, 2008; Duffy et al, 2009). Most
studies have used immunohistological methods to assess protease
expression, and some have identified correlations with tumour
progression and clinical outcome (Brown, 1998; Duffy et al, 2009;
Bourboulia and Stetler-Stevenson, 2010). However, diverse
techniques and a lack of reliable anti-protease antibodies have
contributed to some contradictory observations (Bourboulia and
Stetler-Stevenson, 2010).
An additional pathway hypothesised to play a role in the
expression of ECM-degrading proteases during malignancy is the
c-Met signalling pathway (Peruzzi and Bottaro, 2006; Gentile et al,
2008). On binding to the tyrosine kinase Met cell surface receptor,
hepatocyte growth factor (HGF) activates a programme of cell
dissociation and motility coupled with increased protease produc-
tion, promoting cellular invasion and metastasis (Birchmeier et al,
2003). At present, however, there are little data regarding the role
of the c-Met pathway in OG tumourigenesis.
In the present study, we aimed to investigate the expression of
the entire MMP and TIMP families, a subset of the ADAMs, and
the c-Met signalling pathway, in a cohort of samples of matched
malignant and benign peri-tumoural OG tissue, using quantitative
real-time polymerase chain reaction (PCR). Furthermore, we
aimed to investigate the relationship between gene expression
levels and tumour/patient variables associated with poor prog-
nosis, including age, sex, tumour grade, stage and plasma
C-reactive protein (CRP) concentration (Skipworth et al, 2010).
MATERIALS AND METHODS
Study patients
Patients with a histological diagnosis of OG adenocarcinoma
undergoing surgical resection with curative intent (n¼ 25) were
recruited. Patients were staged according to the AJCC/Interna-
tional Union Against Cancer (Sobin and Wittekind, 2002) (UICC)
criteria before surgical resection. All patients provided written
informed consent and the study was approved by the Lothian
Research Ethics Committee.
Tissue collection
A Consultant Pathologist dissected matched samples of tumour
tissue and peri-tumoural normal tissue from the resected speci-
mens within 20min of the blood supply of the resection specimen
being interrupted. Samples were frozen immediately in liquid
nitrogen using liquid nitrogen-resistant tubes (Corning BV,
Amsterdam, The Netherlands), and stored at  801C until analysis.
RNA extraction and reverse transcription
Total RNA was isolated from the tissue samples by homogenisa-
tion in RNA Bee (Biogenesis Ltd, Poole, UK) using the TissueLyser
(Quiagen, Crawley, UK) followed by the SV Total RNA isolation kit
as described previously (Porter et al, 2004; Riddick et al, 2005).
The RNA quality and concentration were determined using the
NanoDrop ND-1000 UV-Vis spectrophotometer (Labtech, Ring-
mer, UK). Total RNA (1mg) was reverse transcribed with 2mg
random hexamers (Amersham Pharmacia Biotech, Little Chalfont,
UK) and 200 units of SuperScript II reverse transcriptase (Invitrogen,
Cambridge, UK) according to the manufacturer’s instructions
using a GRI DNA Engine (GRI Ltd, Braintree, UK). The cDNA was
diluted 1 : 100 with PCR grade water and stored at  201C.
Quantitative real-time PCR
Specific primers and probes for selected human MMPs, TIMPs,
ADAMs, c-Met and HGF were designed as detailed previously
(Nuttall et al, 2003; Porter et al, 2004; Riddick et al, 2005). The 18S
ribosomal RNA (rRNA) was used as an endogenous control to
normalise for differences in the amount of total RNA in each sample,
using previously validated procedures (Wall and Edwards, 2002).
Polymerase chain reaction reactions were carried out as described
previously (Nuttall et al, 2003) using the ABI 7700 real-time PCR
machine (Applied Biosystems, Carlsbad, CA, USA) with each
reaction containing 5ng of reverse-transcribed RNA (1ng for 18S)
in a 25-ml reaction. The RNA levels (compared with 18S rRNA) in
each sample were determined by performing standard curves for all
target genes covering 1–0.0625ng of RNA for 18S and 20–0.5ng RNA
for all other genes. Genes with cycle threshold (CT) of 40 were
excluded from the analysis as there was no PCR amplification.
Assessment of plasma CRP concentration
Plasma CRP was assayed using automated methods on an Olympus
AU2700 analyser (Olympus Diagnostica GmbH (Irish Branch),
Lismeehan, Ireland), in the Department of Clinical Chemistry,
Royal Infirmary of Edinburgh (fully accredited by Clinical
Pathology Accreditation (UK) Ltd). Appropriate internal quality
controls were included, with CVs typically 3.4% at concentrations
o15mg l 1 and 1.6% at 80mg l 1.
Statistical analysis
All statistical analyses were performed using Statistical Package for
Social Services version 17 (SPSS, Chicago, IL, USA) and GraphPad
Prism version 5 (GraphPad Software Inc., La Jolla, CA, USA).
Malignant gene expression is expressed as a relative level compared
with gene expression in matched benign peri-tumoural samples.
Matched-pair analysis was performed using the Wilcoxon signed-rank
test, whereas non-parametric comparisons were performed using
the Mann–Whitney U-test and Kruskall–Wallis test. Correlation
analysis was performed using Spearman’s Rank Correlation
Coefficient. Box-and-whisker plots of the gene expression levels
(relative to 18S rRNA) in malignant compared with benign OG
tissue are also shown. Statistical significance was set at Po0.05.
RESULTS
Study patients
The median age of the recruited patients (n¼ 25) was 64 years, and
19 (76%) patients were male. Primary tumour sites were
oesophageal (n¼ 16, 64%) and gastric (n¼ 9, 36%). Histological
tumour subtype was adenocarcinoma in all cases. A summary of
patient demographics is shown in Table 1.
Protease expression in matched malignant and benign
OG tissue samples
Expression data for all protease and inhibitor genes are
summarised in Table 2. In total, expression levels of 13 different
MMPs, 2 TIMPs, 6 ADAMs, c-Met and HGF were upregulated
significantly in malignant OG tissue compared with matched
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benign peri-tumoural tissue (Table 2). Genes with the greatest
relative increase in expression in malignant tissue were MMP1, 3,
7, 9, 10, 11, 12, 16 and 24 (Po0.01), each of which demonstrated a
median relative gene expression 44-fold than that of matched
benign samples. Comparative box-and-whisker plots of finite gene
expression levels compared with 18S rRNA are shown in Figure 1
and Supplementary Figures 1 and 2. The protease with the largest
relative increase in expression was MMP11, which had a median
expression in malignant OG tissue 28 times than that of benign
tissue (Po0.001) (Table 2; Figure 1).
Relationship between gene expression and
clinico-pathological variables
Although ADAM8 and ADAM15 expression levels were only B1.5
times that observed in benign tissue, expression levels increased
significantly with worsening tumour stage (P¼ 0.048 and
P¼ 0.044, respectively) (Table 3; Figure 2A and B). The ADAM12
expression also increased significantly with worsening tumour
grade (P¼ 0.011) (Table 3; Figure 2C). Matrix metalloproteinase 19
expression in malignant tissue was significantly greater in women
than men (P¼ 0.015) (Table 3). No significant relationships were
demonstrated between relative mRNA expression and pre-
operative plasma CRP level or patient age.
DISCUSSION
The ECM is a complex structure consisting of many different
proteins, and thus its degradation requires a combination of
proteases (Bourboulia and Stetler-Stevenson, 2010). In order to
understand the complex processes underpinning tumour develop-
ment and invasion, it is important to study the complete range of
proteases that may be responsible. This study is the first
comprehensive analysis of the expression of the MMP, TIMP and
ADAM families in a series of human OG adenocarcinoma samples.
The expression of many MMPs was increased significantly in OG
cancer, particularly MMPs 1, 3, 7, 10, 11, 12 and 24 (Table 2;
Figure 1). The general upregulation of MMPs is consistent with
the concept that tumourigenesis involves the synergistic action of
multiple proteases, causing cell migration, angiogenesis and
modulating cell biology (Kessenbrock et al, 2010).
The protease MMP7 has been the most widely investigated in
previous studies of OG cancer. Increased MMP7 mRNA expression
has been shown in gastric adenocarcinoma (Honda et al, 1996),
whereas elevated MMP7 protein expression has been shown in
both gastric (Honda et al, 1996; Kitoh et al, 2004; Kubben et al,
2006) and oesophageal (Tanioka et al, 2003) malignancies. The
suggested pro-tumourigenic mechanisms of MMP7 may involve
protease activation by Helicobacter pylori (Wroblewski et al, 2003),
and cleavage of the membrane-bound epithelial transmembrane
adhesion molecule E-cadherin, the release of which promotes cell
invasion by disrupting cell–cell contacts (Noe et al, 2001). In-vitro
studies using a gastric cancer cell line have also demonstrated that
MMP7 production is increased by HGF, indicating a role for the
Table 1 Demographics of the patients recruited with oesophago–gastric
cancer (n¼ 25)
Characteristic n (%)
Age (years)
o60 5 (20)
60–69 12 (48)
X70 8 (32)
Sex
Male 19 (76)
Female 6 (24)
Tumour site
Oesophageal 16 (64)
Gastric 9 (36)
Histology
Adenocarcinoma 25 (100)
UICC stage
I 10 (40)
II 7 (28)
III 4 (16)
IV 4 (16)
Tumour grade
Well differentiated 2 (8)
Moderately differentiated 8 (32)
Poorly differentiated 15 (60)
Abbreviation: UICC¼ International Union Against Cancer. Tumour stage and grade
were determined during routine histopathological examination.
Table 2 Relative gene expression in malignant oesophago–gastric tissue
compared with matched benign samples
Gene
Relative upregulation of gene
expression in malignant tissue P-value
MMP1 8.04 o0.001
MMP2 1.21 0.230
MMP3 8.25 o0.001
MMP7 19.83 o0.001
MMP8 ND ND
MMP9 6.23 o0.01
MMP10 15.46 o0.001
MMP11 20.18 o0.001
MMP12 18.56 o0.001
MMP13 0.48 0.855
MMP14 3.65 o0.001
MMP15 0.92 0.458
MMP16 8.86 o0.01
MMP17 5.46 0.117
MMP19 1.43 o0.05
MMP20 ND ND
MMP21 ND ND
MMP23 1.31 o0.05
MMP24 5.76 o0.01
MMP25 3.30 o0.05
MMP26 ND ND
MMP27 1.21 0.528
MMP28 2.42 0.277
TIMP1 2.59 o0.001
TIMP2 1.78 0.170
TIMP3 1.54 o0.05
TIMP4 5.02 0.0657
ADAM8 1.54 o0.01
ADAM9 1.88 o0.01
ADAM10 1.67 o0.001
ADAM12 3.79 o0.01
ADAM15 1.46 o0.01
ADAM17 2.47 o0.001
ADAM19 1.58 0.0534
ADAM28 0.75 0.291
c-Met 4.11 o0.01
HGF 2.63 o0.01
Abbreviations: ND¼ not detected; MMP¼matrix metalloproteinase; TIMP¼ tissue
inhibitors of metalloproteinase; ADAM¼ a disintegrin and metalloproteinase;
HGF¼ hepatocyte growth factor. Relative gene expression was upregulated in
malignant tissue for the majority of proteases. Relative upregulation of mRNA was
determined by calculating the median difference in expression between malignant
and matched benign samples. Data were compared using Wilcoxon signed-rank test.
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c-Met signalling pathway in the pathogenesis of OG cancer
(Lee et al, 2007), a concept that is supported by the increased
malignant expression of HGF and c-Met in the present study.
Of the proteases that were highly upregulated in the present
study, MMP1, 3, 7, 10 and 12 are located in a cluster on chromo-
some 11q22.3 (Jackson et al, 2010), raising the possibility of
co-ordinated expression of these genes. Immunohistochemistry
has demonstrated increased MMP1 (Inoue et al, 1999), MMP10
(Aung et al, 2006), MMP11 (Zhao et al, 2010) and MMP12
(Salmela et al, 2001) expression in gastric adenocarcinoma,
whereas MMP3 is associated with increased risk of oesophageal
adenocarcinoma (Bradbury et al, 2009). These MMPs share similar
promoter conformation, with TATA boxes at around  30 bp and
activator protein-1 transcription factor sites around  70 bp
(Clark et al, 2008). It has been suggested that these MMPs can
be co-regulated by a variety of chemical stimuli, including IL-1 and
TNF-a (Clark et al, 2008).
The MMP with the greatest upregulation in the present study
is MMP11 (Table 2), with a B20-fold increase in expression in
malignant compared with matched benign OG tissue. Zhao et al
(2010) have shown using RT–PCR that MMP11 expression is
elevated in gastric adenocarcinoma and correlated with TNM
stage. Unlike other members of the MMP family, MMP11 does not
degrade classical ECM proteins and instead facilitates the break-
down of the serine protease inhibitors a1-antitrypsin and insulin-
like growth factor binding protein-1 (IGFBP-1) (Nedic et al, 2007).
Insulin-like growth factor-1 inhibits malignant cell apoptosis
through a paracrine mechanism (Zhao et al, 2010); thus IGFBP-1
proteolysis leads to the release of IGF-1, inhibited apoptosis,
and the progression to a more invasive stage of malignancy
(Kasper et al, 2007).
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Figure 1 Box-and-whisker plots of the gene expression (relative to 18S rRNA) of the most highly expressed degradome components in malignant
compared with benign OG tissue (Po0.01). Y-axes show relative mRNA expression compared with 18S rRNA expression (y-axes limited for visual clarity).
Each of these degradome components was expressed in malignant tissue at levels 44-fold that are seen in benign tissue (range 3.65–20.18). Data were
compared using Wilcoxon signed-rank test. K¼Outlier (value 41.5 times the interquartile range beyond the quartiles).
Table 3 Relationship between relative gene expression in malignant
oesophago–gastric tissue and clinico-pathological parameters
Gene Clinico-pathological variable P-value
ADAM8 Tumour stage 0.048
ADAM15 Tumour stage 0.044
ADAM12 Tumour grade 0.011
MMP19 Gender 0.015
Abbreviations: ADAM¼ a disintegrin and metalloproteinase; MMP¼matrix metallo-
proteinase; PCR¼ polymerase chain reaction. Statistical analysis was completed using
Kruskal–Wallis tests to investigate the relationship between protease expression and
tumour stage and grade, and a Mann–Whitney U-test for relationships between gene
expression and gender. Samples with a CT value of 40 denoting no PCR amplification
were excluded before statistical analysis. Values are given to three decimal places.
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Of the remaining MMPs, expression of the gelatinases MMP2
and MMP9 has been shown to be elevated in OG adenocarcinoma
(Sier et al, 1996; Murray et al, 1998; Parsons et al, 1998; Shim et al,
2007; Sampieri et al, 2010). In the present study, MMP9 levels were
increased B2-fold in malignant OG tissue compared with benign,
but MMP2 expression was not significantly different, mirroring
work by Sampieri et al (2010). Tissue inhibitors of metalloprotei-
nase 3, which was elevated in malignant tissue in the current study,
may indirectly influence the expression of MMP2 (Bourboulia and
Stetler-Stevenson, 2010), and thus it is possible that high TIMP3
expression was the cause of the lower MMP2 expression observed.
Tissue inhibitors of metalloproteinases are key regulators of
MMPs, and have an important role in tumourigenesis (Mimori
et al, 1997; Brew and Nagase, 2010). Our data show that the
expression of TIMP1 and 3 were elevated in OG adenocarcinoma.
Classically, it was thought that TIMPs protected against malig-
nancy by inhibiting the proteases responsible for ECM degradation
(Bourboulia and Stetler-Stevenson, 2010), and studies in various
cancers have shown reduced expression (Ko et al, 1998; Riddick
et al, 2005). Gu et al (2008) demonstrated downregulation of
TIMP3 in OG adenocarcinoma and suggested that TIMP3 acts as a
tumour suppressor, inhibiting growth, angiogenesis and invasion.
However, other researchers have revealed increased TIMP expres-
sion in malignancy (Joo et al, 2000; Shim et al, 2007; Brew and
Nagase, 2010), including oesophageal cancer (Salmela et al, 2001).
Tissue inhibitors of metalloproteinase 3 is proposed to induce
apoptosis through inhibition of ADAM17 (TNF-a converting
enzyme), with subsequent stabilisation of TNF receptors (Brew
and Nagase, 2010), supporting the results of this study. The present
study also supports previous investigations that have demon-
strated elevated TIMP1 expression in gastric cancer (Mimori et al,
1997; Murray et al, 1998; Joo et al, 2000). Possible mechanisms
of action for TIMP1 in tumourigenesis involve a combination
of cell-cycle arrest and anti-apoptotic activity, leading to cellular
transformation and invasion (Brew and Nagase, 2010).
The expression levels of the majority of the profiled ADAMs,
namely ADAM8, 9, 10, 12, 15 and 17, were increased significantly
in malignant OG tissue compared with matched benign samples
(Table 2). The ADAM12 demonstrated the highest expression
levels with a relative increase of B4-fold in malignant tissue
(Figure 2). Previous studies have shown that various members of
the ADAM family are increased in several cancer types, including
lung, brain and prostate (Rocks et al, 2008; Duffy et al, 2009), but
few have investigated the role in OG malignancy. The present study
supports the work of Carl-McGrath et al (2005), who used RT–PCR
to show that ADAM9, 12 and 15 expression is elevated in
malignant compared with matched benign gastric tissue. The
authors suggested that these proteases are involved in malignant
transformation via the proteolytic shedding of signalling molecules
and the consequent transactivation of their receptors, such as the
epithelial growth factor receptor and its ligands (Carl-McGrath
et al, 2005). Yoshimura et al (2002) demonstrated upregulation of
ADAM10 and ADAM17, but not ADAM15, in antral gastric
tissue during Helicobacter pylori infection, suggesting that their
expression is upregulated by the bacteria. Furthermore, it is
believed that ADAM17 is important for the release of active TNF-a,
a pro-inflammatory cytokine involved in cancer development via
mucosal inflammation and damage (Yoshimura et al, 2002).
Expression of ADAM8 and ADAM15 in malignant OG
adenocarcinoma correlated with increasing tumour stage, and
ADAM12 expression correlated with tumour grade (Figure 2),
implying that these proteases are potential prognostic markers of
OG adenocarcinoma. The ADAM8 expression has been shown to
correlate significantly with poor prognostic parameters in prostate
(Fritzsche et al, 2006) and brain (Wildeboer et al, 2006) tumours.
However, this is the first study to report ADAM8 expression in OG
malignancy. The ADAM15 is located on chromosome 1 at 1q21.3
(Kuefer et al, 2006), a region known to be amplified in several
types of adenocarcinoma (Glinksy et al, 2003). The ADAM15
digests collagen IV and gelatin and is involved in the promotion of
cell growth (Mochizuki and Okada, 2007). It has shown to be
expressed significantly in gastric adenocarcinoma (Carl-McGrath
et al, 2005), and correlation with tumour stage has been
demonstrated in breast and prostate cancer (Keufer et al, 2006).
Figure 2 suggests that the expression of ADAM8 and ADAM15 in
stage 4 cancers declines to stage 1 levels. Stage 4 disease is
associated with distant (or at least significant nodal) metastases,
and therefore ADAM8 and 15 levels may be reduced at this time in
order to allow the dissociation of tumour cell adhesion and the
process of metastasis. Whether this decline in expression reflects a
causative initiator of metastasis or simply a small component of an
overall metastatic phenomenon remains unclear. Further studies
are required to verify this finding in other patient groups.
A similar link between ADAM12 expression and tumour grade
has been demonstrated previously in malignancies of other tissues
(Kveiborg et al, 2008; Duffy et al, 2009). Frohlich et al (2006)
showed that the level of ADAM12 mRNA and protein expression in
bladder tumour tissue samples correlated with the tumour grade.
Interestingly, the concentration of ADAM12 in the urine of
patients with bladder cancer was significantly elevated compared
with healthy patients (Frohlich et al, 2006), suggesting that
ADAM12 may be secreted by malignant tissue. Furthermore, Roy
et al (2004) have also established a positive correlation between
urinary ADAM12 levels and breast cancer progression. Thus,
patient urine and possibly plasma may be potential biomarker
sources in patients with OG cancer.
In conclusion, this study provides the most detailed profile
to date of the degradome in OG malignancy. It implicates
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Figure 2 Relationship between relative gene expression and tumour stage and grade. (A) ADAM8 expression associated positively with tumour stage
(P¼ 0.048). (B) ADAM15 expression associated positively with tumour stage (P¼ 0.044). (C) ADAM12 expression associated positively with worsening
tumour grade (P¼ 0.011). Horizontal bars show median values. Comparisons were performed using Kruskal–Wallis test. Extreme values are not shown for
visual clarity.
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several MMPs, TIMPs, ADAMs and the c-Met signalling
pathway in OG tumourigenesis. Larger clinical studies are
required to assess the potential predictive and prognostic nature
of these RNAs. Studies of both protein expression and function are
required to identify if these proteins may represent novel
therapeutic targets. However, such studies may be hampered
by the unreliability of anti-protease antibodies.
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